Equities Analysts Issue Forecasts for Travere Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Travere Therapeutics in a research note issued to investors on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of ($1.80) for the year, down from their prior estimate of ($1.71). HC Wainwright has a "Buy" rating and a $19.00 price target on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Travere Therapeutics' FY2026 earnings at $0.20 EPS and FY2027 earnings at $1.98 EPS.

A number of other research analysts have also issued reports on the company. Piper Sandler boosted their price target on Travere Therapeutics from $10.00 to $11.00 and gave the stock a "neutral" rating in a research report on Thursday, January 18th. Wells Fargo & Company boosted their price target on Travere Therapeutics from $8.00 to $9.00 and gave the stock an "equal weight" rating in a research report on Friday, February 16th. Wedbush reiterated an "outperform" rating and set a $13.00 price target on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Finally, Guggenheim reiterated a "neutral" rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Travere Therapeutics has an average rating of "Moderate Buy" and an average target price of $18.00.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded down $0.13 during trading on Friday, reaching $5.26. The stock had a trading volume of 1,220,034 shares, compared to its average volume of 1,268,295. Travere Therapeutics has a one year low of $5.12 and a one year high of $22.75. The stock has a market cap of $400.33 million, a PE ratio of -3.27 and a beta of 0.58. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47. The firm's 50 day moving average price is $7.28 and its two-hundred day moving average price is $7.65.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The company had revenue of $45.06 million for the quarter, compared to the consensus estimate of $41.25 million.

Institutional Trading of Travere Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas raised its holdings in Travere Therapeutics by 9.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 18,804 shares of the company's stock valued at $168,000 after acquiring an additional 1,641 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Travere Therapeutics by 9.7% in the 4th quarter. Arizona State Retirement System now owns 20,969 shares of the company's stock worth $189,000 after buying an additional 1,851 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Travere Therapeutics by 1,656.4% in the 4th quarter. Signaturefd LLC now owns 3,021 shares of the company's stock worth $27,000 after buying an additional 2,849 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Travere Therapeutics by 7.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company's stock worth $417,000 after buying an additional 3,083 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in shares of Travere Therapeutics by 4.5% in the 1st quarter. Rice Hall James & Associates LLC now owns 73,400 shares of the company's stock worth $566,000 after buying an additional 3,140 shares in the last quarter.

Insider Buying and Selling at Travere Therapeutics

In other news, insider Peter Heerma sold 4,195 shares of the company's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.53, for a total transaction of $35,783.35. Following the completion of the sale, the insider now owns 99,503 shares in the company, valued at approximately $848,760.59. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Peter Heerma sold 4,195 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total transaction of $35,783.35. Following the completion of the sale, the insider now owns 99,503 shares in the company, valued at approximately $848,760.59. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP William E. Rote sold 4,764 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.71, for a total value of $41,494.44. Following the sale, the senior vice president now owns 80,720 shares of the company's stock, valued at approximately $703,071.20. The disclosure for this sale can be found here. Insiders have sold 34,773 shares of company stock worth $300,625 over the last 90 days. 3.75% of the stock is currently owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.